Effects of a Motor Imagery Exercise Protocol in Patients With Fibromyalgia

Sponsor
University of Roma La Sapienza (Other)
Overall Status
Completed
CT.gov ID
NCT03870932
Collaborator
(none)
29
1
2
26
1.1

Study Details

Study Description

Brief Summary

The aim of this study was to evaluate the efficacy of a novel approach with a motor imagery-based exercise program versus conventional rehabilitative approach in fibromyalgia syndrome (FM): reduction of pain was set as the primary outcome.

Condition or Disease Intervention/Treatment Phase
  • Other: Motor Imagery physical therapy
  • Other: Conventional physical therapy
N/A

Detailed Description

Evidence about the therapeutic efficacy of exercise intervention programs in FM is still low and many authors suggested improving standardized exercise prescription for FM to achieve optimal results. In the literature, as an alternative approach, rehabilitative protocols in Group Music and Imagery seem to improve well-being and reduce anxiety in women with FM and suggest that Music and Imagery may help diminish pain intensity and depression. A rehabilitative approach should also consider the psychological and emotional aspects and, when possible, be accompanied by cognitive-behavioral therapy. The purpose of this research is to evaluate the possible efficacy of a novel approach with a motor imagery-based exercise program versus conventional rehabilitative approach in FM syndrome: the reduction of pain was set as the primary outcome as well as taking into account the patient's psychological and emotional condition. This study was designed as a double-blind, randomized, controlled trial.

Study Design

Study Type:
Interventional
Actual Enrollment :
29 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effects of a Motor Imagery Exercise Protocol on Chronic Pain and Emotional Distress in Patients With Fibromyalgia: a Pilot Study
Actual Study Start Date :
Jul 1, 2016
Actual Primary Completion Date :
Dec 15, 2017
Actual Study Completion Date :
Aug 30, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Motor imagery rehabilitative group (MIG)

All patients performed 10 treatment sessions, lasting 60 to 90 minutes, twice a week, in groups of three to four patients. The gold standard was to choose simple and safe exercises in order to encourage the patient to repeat the schedule at home. The exercises proposed in the MIG have been chosen respecting the following principles: slowness, painlessness, promoting attention, easy to imagine. The main purpose of motor imagery-based exercises was to bring the patient back to "feeling and self-perceiving" the execution of the movement. More than the "quantity" of repetition, the "quality" of the movement, free from pain, was important.

Other: Motor Imagery physical therapy

Active Comparator: Control rehabilitative Group (CG)

The CG received a conventional rehabilitation protocol, based on ten 1-hour sessions, held twice a week (over a 5-week period), previously investigated as efficient in FM by the authors and published. The exercises included low-to-moderate impact aerobic training, walking in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes), for a total of 20 consecutive minutes, posture exercises for the back and proprioceptive exercises for the trunk, to improve axial stability. Each exercise was repeated 10 times (3 sets of 10), with a resting period of at least 3 minutes between sets. All sessions ended with stretching and diaphragmatic breathing exercises.

Other: Conventional physical therapy

Outcome Measures

Primary Outcome Measures

  1. Fibromyalgia Impact Questionnaire (FIQ) [0-4-12 weeks]

    self-administered instrument to assess the current health status of patients with fibromyalgia

  2. Health Assessment Questionnaire (HAQ) [0-4-12 weeks]

    comprehensive measure of outcome in patients with a wide variety of chronic diseases

  3. Fibromyalgia Assessment Status (FAS) [0-4-12 weeks]

    self-administered index that combines fatigue, sleep disturbances and pain in 16 non-articular sites

  4. Visual Analogue Scale (VAS) [0-4-12 weeks]

    Instrument to assess unidimensional measure of pain intensity. VAS was presented in a coloured scale with a middle point, graduations and numbers. Under the scale there was a straight horizontal line of fixed length, 100 mm. The ends were defined as the limits of the parameter to be measured (pain in the last 24 hours), orientated from the left (worst, no pain) to the right (best, worst pain to be imagined). The score is determined by measuring the distance (cm) on the 10 cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-10.

  5. Hamilton Anxiety Rating Scale (HAM-A) [0-4-12 weeks]

    Instrument to assess anxiety severity. The HAM-A was one of the first rating scales developed to measure the severity of anxiety symptoms. The scale consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. It was administered by a clinician experienced in working with psychiatric patients.

  6. Hamilton Depression Scale (HAM-D) [0-4-12 weeks]

    Otherwise known as Hamilton Rating Scale for Depression or HRSD-17. The patient is rated by a clinician on 21 items scored either on a 3-point or 5-point Likert-type scale. Although the form lists 21 items, the scoring is based on the first 17. It generally takes 15-20 minutes to complete the interview and score the results. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. A score of 0-7 is considered to be normal while a score of 20 or higher indicates at least moderate severity.

  7. 20-Item Toronto Alexithymia Scale (TAS-20) [0-4-12 weeks]

    Instrument to assess alexithymia severity. The TAS is a 20-item instrument with 3 subscales: 1) difficulty Describing Feelings subscale, is used to measure difficulty describing emotions. 5 items; 2) difficulty Identifying Feeling subscale is used to measure difficulty identifying emotions. 7 items; 3) Externally-Oriented Thinking subscale, is used to measure the tendency of individuals to focus their attention externally. 8 items. The scale is a self-report scale that is comprised of 20 items. Items are rated using a 5-point Likert scale whereby 1 = strongly disagree and 5 = strongly agree. There are 5 items that are negatively keyed (items 4, 5, 10, 18 and 19). The total alexithymia score is the sum of responses to all 20 items, while the score for each subscale factor is the sum of the responses to that subscale. The TAS-20 uses cutoff scoring: equal to or less than 51 = non-alexithymia, equal to or greater than 61 = alexithymia. Scores of 52 to 60 = possible alexithymia.

  8. Coping Orientation to the Problems Experienced (COPE-NIV) [0-4-12 weeks]

    instrument for measuring a broad range of coping styles

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • experienced widespread pain for more than 3 months

  • pain with 4 kg/cm2 pressure at 11 or more of the 18 tender points

  • aged 18 to 60 years

  • pharmacological therapeutic regimen must have been stable for at least three months before

Exclusion Criteria:
  • pregnant women

  • pacemaker wearers

  • overlapping painful conditions

  • presence of autoimmune or hematologic diseases

  • psychiatric disorders in pharmacological and psychological treatment

  • other causes of chronic pain

  • other diseases such as epilepsy, tumors, major neurological problems and diabetes

Contacts and Locations

Locations

Site City State Country Postal Code
1 Umberto I Hospital Rome Italy 00165

Sponsors and Collaborators

  • University of Roma La Sapienza

Investigators

  • Principal Investigator: Teresa Paolucci, MD, PhD, Università "Sapienza" Roma

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Teresa Paolucci, Assistant Medical Director (Physiatrist), University of Roma La Sapienza
ClinicalTrials.gov Identifier:
NCT03870932
Other Study ID Numbers:
  • URomLS-2018
First Posted:
Mar 12, 2019
Last Update Posted:
May 14, 2019
Last Verified:
May 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Teresa Paolucci, Assistant Medical Director (Physiatrist), University of Roma La Sapienza
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 14, 2019